Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 13/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915849 | 0.88 | GABRP (0.42) | BRD4QPCTAGER | |
| SCHEMBL19915909 | 0.88 | BRD4 (0.44) | BRD4TRPV4QPCTAGERJAK2 | |
| SCHEMBL11331901 | 0.81 | BRD4 (0.49) | BRD4TRPV4QPCTAGERJAK2 | |
| SCHEMBL19848088 | 0.79 | BRD4 (0.45) | BRD4TRPV4QPCTAGERJAK2 | |
| SCHEMBL19911333 | 0.78 | TNF (0.44) | — | |
| SCHEMBL2311276 | 0.78 | MAPT (0.47) | QPCTMAP3K14 | |
| SCHEMBL19911438 | 0.78 | QPCT (0.39) | BRD4QPCT | |
| SCHEMBL19848346 | 0.78 | BRD4 (0.44) | BRD4TRPV4QPCTAGERJAK2 | |
| SCHEMBL19553628 | 0.78 | POLB (0.55) | BRD4TRPV4QPCTAGERJAK2 | |
| SCHEMBL17103033 | 0.78 | BRD4 (0.44) | BRD4TRPV4QPCTAGER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | BRD4 2/4885TRPV4 903/4885QPCT 830/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | BRD4 2/4885TRPV4 903/4885QPCT 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.